Innovations in Efforts to Expand Treatment for Opioid Use Disorder

Overview

Journal Prev Med

Specialty Public Health

Date 2019 Aug 25

PMID 31445112

Citations 8

Authors

Stacey C Sigmon

Affiliations

Soon will be listed here.

Abstract

Fewer than 20% of Americans with opioid use disorder receive empirically-supported treatment. There is a critical need for innovative approaches to support expansion of evidence-based opioid treatment, particularly in rural geographic areas so impacted by the current opioid public health crisis. Doing so will require more diverse pathways into treatment, novel pharmacological tools, improved integration and efficiency among treatment modalities, and harm reduction when treatment is not available. In this invited commentary, we review exciting recent efforts to accomplish these aims as well as offer additional considerations for future clinical and research efforts to increase the availability of treatment for opioid use disorder.

Citing Articles

Effects of the Communities that Heal (CTH) intervention on perceived opioid-related community stigma in the HEALing Communities Study: results of a multi-site, community-level, cluster-randomized trial.

Davis A, Knudsen H, Walker D, Chassler D, Lunze K, Westgate P Lancet Reg Health Am. 2024; 32:100710.

PMID: 38510790 PMC: 10950860. DOI: 10.1016/j.lana.2024.100710.

A scoping review of community-based post-opioid overdose intervention programs: implications of program structure and outcomes.

Bailey A, Harrington C, Evans E Health Justice. 2023; 11(1):3.

PMID: 36707446 PMC: 9883127. DOI: 10.1186/s40352-022-00201-w.

Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.

Andraka-Christou B, Saloner B, Gordon A, Totaram R, Randall-Kosich O, Golan M Am J Drug Alcohol Abuse. 2022; 48(4):492-503.

PMID: 35772010 PMC: 10336699. DOI: 10.1080/00952990.2022.2082301.

Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.

Gregory H, Hill V, Parker R Cureus. 2022; 13(11):e19870.

PMID: 34976492 PMC: 8712194. DOI: 10.7759/cureus.19870.

Opioid Treatment Deserts: Concept development and application in a US Midwestern urban county.

Hyder A, Lee J, Dundon A, Southerland L, All D, Hammond G PLoS One. 2021; 16(5):e0250324.

PMID: 33979342 PMC: 8115812. DOI: 10.1371/journal.pone.0250324.

References

Sigmon S, Bigelow G . Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential. Addiction. 2016; 112(3):386-387. DOI: 10.1111/add.13539. View

Fanucchi L, Lofwall M . Putting Parity into Practice - Integrating Opioid-Use Disorder Treatment into the Hospital Setting. N Engl J Med. 2016; 375(9):811-3. DOI: 10.1056/NEJMp1606157. View

Lofwall M, Walsh S, Nunes E, Bailey G, Sigmon S, Kampman K . Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. JAMA Intern Med. 2018; 178(6):764-773. PMC: 6145749. DOI: 10.1001/jamainternmed.2018.1052. View

Peles E, Schreiber S, Adelson M . Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry. J Addict Med. 2013; 7(3):177-82. DOI: 10.1097/ADM.0b013e318287cfc9. View

Bachhuber M, Thompson C, Prybylowski A, Benitez MSW J, Mazzella MA S, Barclay D . Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abus. 2018; 39(2):167-172. PMC: 9333078. DOI: 10.1080/08897077.2018.1443541. View

Gordon M, Kinlock T, Schwartz R, Fitzgerald T, OGrady K, Vocci F . A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014; 142:33-40. PMC: 4129444. DOI: 10.1016/j.drugalcdep.2014.05.011. View

Vona-Davis L, Rose D . The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009; 18(6):883-93. DOI: 10.1089/jwh.2008.1127. View

Nasser A, Greenwald M, Vince B, Fudala P, Twumasi-Ankrah P, Liu Y . Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder. J Clin Psychopharmacol. 2015; 36(1):18-26. PMC: 5549150. DOI: 10.1097/JCP.0000000000000434. View

Weintraub E, Greenblatt A, Chang J, Himelhoch S, Welsh C . Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018; 27(8):612-617. DOI: 10.1111/ajad.12805. View

10.

Rosenthal R, Lofwall M, Kim S, Chen M, Beebe K, Vocci F . Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. JAMA. 2016; 316(3):282-90. DOI: 10.1001/jama.2016.9382. View

11.

Lee J, McNeely J . Commentary on Jones & McCance-Katze (2019): Buprenorphine and the glass half full-why can't we prescribe more of it, and will nurse practitioners and physician assistants fulfill a chronic unmet need?. Addiction. 2019; 114(3):483-484. DOI: 10.1111/add.14545. View

12.

Saloner B, Karthikeyan S . Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013. JAMA. 2015; 314(14):1515-7. DOI: 10.1001/jama.2015.10345. View

13.

Krawczyk N, Buresh M, Gordon M, Blue T, Fingerhood M, Agus D . Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. J Subst Abuse Treat. 2019; 103:1-8. PMC: 6612429. DOI: 10.1016/j.jsat.2019.05.002. View

14.

DOnofrio G, OConnor P, Pantalon M, Chawarski M, Busch S, Owens P . Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015; 313(16):1636-44. PMC: 4527523. DOI: 10.1001/jama.2015.3474. View

15.

Eibl J, Gauthier G, Pellegrini D, Daiter J, Varenbut M, Hogenbirk J . The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 2017; 176:133-138. DOI: 10.1016/j.drugalcdep.2017.01.048. View

16.

E Blevins C, Rawat N, Stein M . Gaps in the Substance Use Disorder Treatment Referral Process: Provider Perceptions. J Addict Med. 2018; 12(4):273-277. PMC: 6066414. DOI: 10.1097/ADM.0000000000000400. View

17.

Rawson R, Cousins S, McCann M, Pearce R, Van Donsel A . Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system. J Subst Abuse Treat. 2018; 97:84-90. DOI: 10.1016/j.jsat.2018.11.003. View

18.

Streck J, Ochalek T, Badger G, Sigmon S . Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms. Exp Clin Psychopharmacol. 2018; 26(4):403-409. PMC: 6072576. DOI: 10.1037/pha0000199. View

19.

Brooklyn J, Sigmon S . Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact. J Addict Med. 2017; 11(4):286-292. PMC: 5537005. DOI: 10.1097/ADM.0000000000000310. View

20.

Sigmon S, Ochalek T, Meyer A, Hruska B, Heil S, Badger G . Interim Buprenorphine vs. Waiting List for Opioid Dependence. N Engl J Med. 2016; 375(25):2504-2505. PMC: 5373028. DOI: 10.1056/NEJMc1610047. View